Monthly Archives: January 2014

Biothera Further Elucidates the Mechanism of Action of Cancer Immunotherapy Imprime PGG

Research Published in Glycobiology EAGAN, MN – January 30, 2014 – Imprime PGG®, the phase 3 cancer immunotherapy drug from Biothera, utilizes distinct receptors and signaling pathways in monocytes to induce cytotoxic function. The research was published in the latest issue of Glycobiology. This new research describes how structurally different forms of yeast beta glucans utilize different receptors and associated signaling pathways to activate innate...

Read More


Biothera Names VP of Biomarker Development

EAGAN, MN — January 27, 2014 — Peter J. Maimonis, Ph.D. has joined Biothera as Vice President of Biomarker Development and will lead the development and commercialization of assays for the company’s Phase 3 cancer immunotherapy, Imprime PGG®. Dr. Maimonis previously held several senior positions with various pharmaceutical and diagnostic companies, including Senior Director – Cancer Cell Biology, On-Q-ity; Vice President – Biology R&D, Decision...

Read More


Biothera Research Shows Potential for Treating Imprime PGG Biomarker-Negative Cancer Patients

Treatment Option Can Now Work in Vast Majority of Cancer Patients EAGAN, MN — January 16, 2014 — Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG® in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute’s Antibody-Drug Conjugates/ Engineering Targeted Therapeutics...

Read More


Positive Results Presented from Phase 2 Clinical Trial of Biothera’s Imprime PGG Cancer Immunotherapy in Non-Small Lung Cancer Patients

In data presented at an AACR-IASLC joint conference, Imprime PGG met primary endpoint with an Objective Response Rate more than double that of the control group and even greater in Imprime PGG biomarker-positive subgroup. Median Overall Survival for the biomarker-positive Imprime PGG treated subgroup was over 5 months greater than that of the control group. EAGAN, MN — January 7, 2014 — Biothera today reported...

Read More